Status:
COMPLETED
Resveratrol In Chronic Obstructive Pulmonary Disease (COPD) Patients (CARMENS-trial)
Lead Sponsor:
Maastricht University Medical Center
Collaborating Sponsors:
The Netherlands Asthma Foundation
DSM Nutritional Products, Inc.
Conditions:
Pulmonary Disease, Chronic Obstructive
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The primary objective is to investigate the efficacy of resveratrol on mitochondrial function in patients with COPD. The secondary objective is to investigate the effect of resveratrol on body composi...
Detailed Description
Rationale: Patients with COPD are often chaacterized by disturbed metabolic health affecting physical and cognitive function, which is reflected in altered body composition. current studies in healthy...
Eligibility Criteria
Inclusion
- COPD patients
- Current or ex-smoker
- Age \>18 years
Exclusion
- COPD patients planned for pulmonary rehabilitation or who recently participated in a rehabilitation program in the previous 6 months
- Investigator's uncertainty about willingness or ability of the patient to comply with the protocol requirements
- Participation in any other study involving investigational exercise training, nutritional or pharmacological intervention
- Oral glucocorticoid use
- Recent exacerbation (\<4 weeks) that required oral steroids and/or hospital admission
- Subject is pregnant, planning to be pregnant during the study period, lactating, or women who consider themselves to be of childbearing potential and who are engaged in an active sex life and are unwilling to commit to the use of an approved form of contraception throughout the study period. The method of contraception must be recorded in the source documentation;
- Diabetes mellitus (all types), active cardiovascular disease or a cardiovascular event (such as myocardial infarction, cerebrovascular haemorrhage/infarction) in the previous 6 months, recent major surgery, thyroid dysfunction, hepatic or renal disorders, current malignancy (except for dermal malignancies) or central or obstructive sleep apnea;
- Current alcohol consumption \> 20 grams alcohol/day;
- Intake of resveratrol containing dietary supplements.
Key Trial Info
Start Date :
January 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2017
Estimated Enrollment :
23 Patients enrolled
Trial Details
Trial ID
NCT02245932
Start Date
January 1 2015
End Date
November 1 2017
Last Update
May 17 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Maastricht University Medical Center
Maastricht, Limburg, Netherlands